JP7258009B2 - 抗増殖化合物及びその使用方法 - Google Patents

抗増殖化合物及びその使用方法 Download PDF

Info

Publication number
JP7258009B2
JP7258009B2 JP2020500862A JP2020500862A JP7258009B2 JP 7258009 B2 JP7258009 B2 JP 7258009B2 JP 2020500862 A JP2020500862 A JP 2020500862A JP 2020500862 A JP2020500862 A JP 2020500862A JP 7258009 B2 JP7258009 B2 JP 7258009B2
Authority
JP
Japan
Prior art keywords
compound
multiple myeloma
pharmaceutical composition
days
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020500862A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020526534A5 (https=
JPWO2019014100A5 (https=
JP2020526534A (ja
Inventor
ディー．アレクサンダー マシュー
ディー．サード アートマン ジェラルド
エル．ブレイ ゴードン
カーマイケル ジェイムス
カルランシオ ソラヤ
イー．キャザース ブライアン
ディー．コルレア マシュー
ハンセン ジョシュア
ジー．ハベンス コートニー
エス．ケルチャー ティモシー
ロペス‐ジローナ アントニア
ル シャオリング
マン ホン‐ワフ
エー．ナギー マーク
ケー．ナルラ ラマ
アール．ピクコッティ ジョゼフ
ダブリュー．ピアース ダニエル
エー．タバレス‐グレコ ポーラ
ダブリュー．ホワイトフィールド ブランドン
エル．ウォング リリー
ゾウ ナンフェイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of JP2020526534A publication Critical patent/JP2020526534A/ja
Publication of JP2020526534A5 publication Critical patent/JP2020526534A5/ja
Publication of JPWO2019014100A5 publication Critical patent/JPWO2019014100A5/ja
Application granted granted Critical
Publication of JP7258009B2 publication Critical patent/JP7258009B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2020500862A 2017-07-10 2018-07-09 抗増殖化合物及びその使用方法 Active JP7258009B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762530778P 2017-07-10 2017-07-10
US62/530,778 2017-07-10
US201762593185P 2017-11-30 2017-11-30
US62/593,185 2017-11-30
US201862675581P 2018-05-23 2018-05-23
US62/675,581 2018-05-23
PCT/US2018/041230 WO2019014100A1 (en) 2017-07-10 2018-07-09 ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF

Publications (4)

Publication Number Publication Date
JP2020526534A JP2020526534A (ja) 2020-08-31
JP2020526534A5 JP2020526534A5 (https=) 2022-11-02
JPWO2019014100A5 JPWO2019014100A5 (https=) 2022-11-02
JP7258009B2 true JP7258009B2 (ja) 2023-04-14

Family

ID=63036419

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020500862A Active JP7258009B2 (ja) 2017-07-10 2018-07-09 抗増殖化合物及びその使用方法

Country Status (28)

Country Link
US (5) US10357489B2 (https=)
EP (2) EP4467143B1 (https=)
JP (1) JP7258009B2 (https=)
KR (1) KR102656934B1 (https=)
CN (1) CN110869021B (https=)
AU (2) AU2018301335B2 (https=)
CA (1) CA3069138A1 (https=)
CL (1) CL2020000060A1 (https=)
CO (1) CO2020000193A2 (https=)
DK (1) DK3651766T3 (https=)
EC (1) ECSP20001149A (https=)
ES (1) ES2992913T3 (https=)
FI (1) FI3651766T3 (https=)
HR (1) HRP20241553T1 (https=)
HU (1) HUE069137T2 (https=)
IL (1) IL271889B2 (https=)
LT (1) LT3651766T (https=)
MX (1) MX2023000085A (https=)
PL (1) PL3651766T3 (https=)
PT (1) PT3651766T (https=)
RS (1) RS66162B1 (https=)
SA (1) SA520411007B1 (https=)
SG (1) SG11202000143PA (https=)
SI (1) SI3651766T1 (https=)
SM (1) SMT202400470T1 (https=)
TW (2) TWI791552B (https=)
WO (1) WO2019014100A1 (https=)
ZA (1) ZA202000157B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022516989A (ja) * 2019-01-09 2022-03-03 セルジーン コーポレイション （ｓ）－４－（４－（４－（（（２－（２，６－ジオキソピペリジン－３－イル）－１－オキソイソインドリン－４－イル）オキシ）メチル）ベンジル）ピペラジン－１－イル）－３－フルオロベンゾニトリルを含む医薬組成物及びその使用方法
JP2022518175A (ja) * 2019-01-09 2022-03-14 セルジーン コーポレイション （ｓ）－４－（４－（４－（（（２－（２，６－ジオキソピペリジン－３－イル）－１－オキソイソインドリン－４－イル）オキシ）メチル）ベンジル）ピペラジン－１－イル）－３－フルオロベンゾニトリルを含む固体形態及びその塩、ならびにそれらを含む組成物及びその使用方法

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI791552B (zh) * 2017-07-10 2023-02-11 美商西建公司 抗增生化合物及其使用方法
JP2021519337A (ja) 2018-03-26 2021-08-10 シー４ セラピューティクス， インコーポレイテッド Ｉｋａｒｏｓの分解のためのセレブロン結合剤
CN118344338A (zh) 2018-04-23 2024-07-16 细胞基因公司 取代的4-氨基异吲哚啉-1,3-二酮化合物以及它们用于治疗淋巴瘤的用途
EA202092830A1 (ru) * 2018-05-23 2021-04-08 Селджин Корпорейшн Антипролиферативные соединения и биспецифические антитела к bcma и cd3 для комбинированного применения
BR112020023756A2 (pt) 2018-05-23 2021-02-09 Celgene Corporation tratamento de mieloma múltiplo e uso de biomarcadores para 4-(4-(4-(((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-4-il)oxi)metil)benzil)piperazin-1-il)-3-fluorobenzonitrila
DK3820573T3 (da) 2018-07-10 2023-10-23 Novartis Ag 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidin-2,6-dion-derivativer og anvendelse deraf ved behandling af ikaros family zinc finger 2 (ikzf2)-afhængige sygdomme
CA3105813A1 (en) * 2018-07-11 2020-01-16 Celgene Corporation Uses of anti-bcma chimeric antigen receptors
WO2020097403A1 (en) 2018-11-08 2020-05-14 Juno Therapeutics, Inc. Methods and combinations for treatment and t cell modulation
WO2020146440A1 (en) * 2019-01-09 2020-07-16 Celgene Corporation Antiproliferative compounds and second active agents for use in treating multiple myeloma
AR119715A1 (es) * 2019-04-12 2022-01-05 Celgene Corp Métodos para tratar linfoma no hodgkin con el uso de 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)bencil)amino)isoindolin-1,3-diona
CN120172958A (zh) 2019-04-12 2025-06-20 C4医药公司 Ikaros和aiolos的三环降解物
US11666579B2 (en) 2019-10-21 2023-06-06 Celgene Corporation Methods of treating hematological malignancies using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione
WO2021105335A1 (en) 2019-11-27 2021-06-03 Captor Therapeutics S.A. Piperidine-2, 6-dione derivatives which bind to cereblon, and methods of use thereof
AU2020392427B2 (en) 2019-11-27 2024-03-07 Captor Therapeutics S.A. Piperidine-2, 6-dione derivatives which bind to cereblon, and methods of use thereof
US20230114674A1 (en) 2020-01-20 2023-04-13 Kangpu Biopharmaceuticals, Ltd. Isoindoline derivative, and pharmaceutical composition and use thereof
CA3170064A1 (en) * 2020-04-17 2021-10-21 Marcos SAINZ Modulators of mas-related g-protein receptor x4 and related products and methods
CN116157125A (zh) * 2020-04-28 2023-05-23 朱诺治疗学股份有限公司 针对bcma的t细胞疗法与免疫调节化合物的组合
JP2023524068A (ja) * 2020-04-30 2023-06-08 ブリストル－マイヤーズ スクイブ カンパニー サイトカイン関連有害事象を治療する方法
CN115916191A (zh) 2020-06-25 2023-04-04 新基公司 用组合疗法治疗癌症的方法
CN113896711A (zh) * 2020-07-06 2022-01-07 北京诺诚健华医药科技有限公司 杂环类免疫调节剂
US12472176B2 (en) 2020-07-07 2025-11-18 Celgene Corporation Pharmaceutical compositions comprising (S)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile and methods of using the same
EP4183781A4 (en) * 2020-07-20 2024-01-03 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Sulfur-containing isoindoline derivative, and preparation method therefor and medical use thereof
KR20230048373A (ko) 2020-08-03 2023-04-11 캡터 테라퓨틱스 에스.에이. 저분자량 단백질 분해제 및 이의 응용
WO2022146151A1 (en) 2020-12-30 2022-07-07 Captor Therapeutics S.A. Novel compounds which bind to cereblon, and methods of use thereof
CN114685429A (zh) * 2020-12-31 2022-07-01 江苏恒瑞医药股份有限公司 碳链环己二酰亚胺类化合物、其制备方法及其在医药上的应用
JP2024504932A (ja) 2021-01-13 2024-02-02 モンテ ローザ セラピューティクス， インコーポレイテッド イソインドリノン化合物
EP4347037A1 (en) 2021-05-27 2024-04-10 Celgene Corporation Methods of treating multiple myeloma using combination therapy
WO2022255889A1 (en) 2021-06-01 2022-12-08 Captor Therapeutics S.A. Compounds which bind to cereblon, and use thereof
WO2022255890A1 (en) 2021-06-01 2022-12-08 Captor Therapeutics S.A. Compounds which bind to cereblon, and use thereof
EP4380582A1 (en) 2021-08-06 2024-06-12 Celgene Corporation Compositions and methods for selective degradation of engineered proteins
CN116023319A (zh) * 2021-10-25 2023-04-28 英格尔医药科技(上海)有限公司 制备布瓦西坦的方法
WO2023138647A1 (zh) 2022-01-19 2023-07-27 江苏恒瑞医药股份有限公司 一种含硫异吲哚啉类衍生物的晶型
CN116462660A (zh) * 2022-01-19 2023-07-21 江苏恒瑞医药股份有限公司 一种异喹啉酮类化合物的盐及其晶型
WO2024167423A1 (en) 2023-02-07 2024-08-15 Captor Therapeutics S.A. Gspt1 degrader compounds

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013519675A (ja) 2010-02-11 2013-05-30 セルジーン コーポレイション アリールメトキシイソインドリン誘導体、それを含む組成物、及びその使用方法
JP2015524478A (ja) 2012-08-09 2015-08-24 セルジーン コーポレイション ３−（４−（（４−（モルホリノメチル）ベンジル）オキシ）−１−オキソイソインドリン−２−イル）ピペリジン−２，６−ジオンを使用する癌の治療方法

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0011312A1 (en) 1977-07-09 1980-05-28 LUCAS INDUSTRIES public limited company Road vehicle electrical systems
DE2848746A1 (de) 1978-11-10 1980-05-22 Wolfgang Arheiliger Dichtung fuer eine schwellenlose tuere mit drehfluegel
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5855887A (en) 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
US5948893A (en) 1996-01-17 1999-09-07 The United States Of America As Represented By The Secretary Of The Navy Murine hybridoma and antibody binding to CD28 receptor secreted by the hybridoma and method of using the antibody
US6207157B1 (en) 1996-04-23 2001-03-27 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for nontypeable Haemophilus influenzae
WO2000034437A2 (en) 1998-12-08 2000-06-15 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
IL148079A0 (en) 1999-08-24 2002-09-12 Medarex Inc Human ctla-4 antibodies and compositions containing the same
WO2003042402A2 (en) 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
CN1753912B (zh) 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
US20060074103A1 (en) 2004-10-06 2006-04-06 Corte James R Cyclic beta-amino acid derivatives as factor Xa inhibitors
RU2494107C2 (ru) 2005-05-09 2013-09-27 Оно Фармасьютикал Ко., Лтд. Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
GB0514018D0 (en) 2005-07-07 2005-08-17 Ionix Pharmaceuticals Ltd Chemical compounds
JP4855485B2 (ja) 2006-02-17 2012-01-18 エフ．ホフマン−ラ ロシュ アーゲー ５ｈｔ２／ｄ３モジュレーターとしてのベンゾイル−ピペリジン誘導体
WO2008091670A2 (en) 2007-01-24 2008-07-31 Polyera Corporation Organic semiconductor materials and precursors thereof
KR101791757B1 (ko) 2007-03-20 2017-10-30 셀진 코포레이션 4'-ｏ-치환된 아이소인돌린 유도체 및 이를 포함하는 조성물 및 이의 사용 방법
HRP20131167T1 (hr) 2007-06-18 2014-01-03 Merck Sharp & Dohme B.V. Antitijela za humani receptor programirane smrti pd-1
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
KR101814408B1 (ko) 2008-09-26 2018-01-04 다나-파버 캔서 인스티튜트 인크. 인간 항-ｐｄ-１, ｐｄ-ｌ１, 및 ｐｄ-ｌ2 항체 및 그의 용도
US8628927B2 (en) 2008-11-07 2014-01-14 Sequenta, Inc. Monitoring health and disease status using clonotype profiles
WO2010057087A1 (en) 2008-11-17 2010-05-20 Plextronics, Inc. Organic photovoltaic devices comprising substituted endohedral metallofullerenes
AU2009333580B2 (en) 2008-12-09 2016-07-07 Genentech, Inc. Anti-PD-L1 antibodies and their use to enhance T-cell function
CA2744563A1 (en) 2008-12-12 2010-06-17 Ariad Pharmaceuticals, Inc. Azaindole derivatives as kinase inhibitors
WO2010089411A2 (en) 2009-02-09 2010-08-12 Universite De La Mediterranee Pd-1 antibodies and pd-l1 antibodies and uses thereof
WO2011066342A2 (en) 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
WO2011082400A2 (en) 2010-01-04 2011-07-07 President And Fellows Of Harvard College Modulators of immunoinhibitory receptor pd-1, and methods of use thereof
US20110312996A1 (en) 2010-05-17 2011-12-22 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
JP2013532153A (ja) 2010-06-18 2013-08-15 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 慢性免疫病に対する免疫治療のためのｔｉｍ−３およびｐｄ−１に対する二重特異性抗体
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
AR082986A1 (es) 2010-09-14 2013-01-23 Exelixis Inc DERIVADOS DE PURINA COMO INHIBIDORES DE PI3K-d, METODOS PARA SU PREPARACION, FORMULACIONES FARMACEUTICAS QUE LOS COMPRENDEN Y SU USO EN EL TRATAMIENTO DE ENFERMEDADES HIPERPROLIFERATIVAS
JP5728921B2 (ja) 2010-12-10 2015-06-03 コニカミノルタ株式会社 光学フィルム、及びそれを用いた偏光板、液晶表示装置
EP2651405A2 (en) 2010-12-14 2013-10-23 Electrophoretics Limited Casein kinase 1 (ck1 ) inhibitors
AU2012236655B2 (en) 2011-03-28 2016-09-22 Deuterx, Llc, 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds
EP2694489B1 (en) 2011-04-07 2017-09-06 Merck Sharp & Dohme Corp. C5-c6 oxacyclic-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
TW201408652A (zh) 2012-07-11 2014-03-01 Hoffmann La Roche 作爲ＲＯＲｃ調節劑之芳基磺內醯胺衍生物
ES2814952T3 (es) 2012-09-04 2021-03-29 Celgene Corp Isotopólogos de 3-(5-amino-2-metil-4-oxoquinazolin-3(4H)-il) piperidina-2-6-diona y métodos de preparación de los mismos
US9695145B2 (en) 2013-01-22 2017-07-04 Celgene Corporation Processes for the preparation of isotopologues of 3-(4-((4- morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
BR112016003609B1 (pt) 2013-08-22 2021-04-27 Vanda Pharmaceuticals Inc Uso de tricostatina a em tratamento de mieloma múltiplo (mm)
WO2016012965A2 (en) 2014-07-25 2016-01-28 Piramal Enterprises Limited Substituted phenyl alkanoic acid compounds as gpr120 agonists and uses thereof
WO2016019386A1 (en) 2014-08-01 2016-02-04 Green Revolution Cooling, Inc. Controller for oil-cooled rack with multiple modes of operation
US10668171B2 (en) 2015-05-30 2020-06-02 Ptc Therapeutics, Inc. Methods for modulating RNA splicing
WO2017005900A1 (en) 2015-07-08 2017-01-12 F. Hoffmann-La Roche Ag ARYL SULTAM DERIVATIVES AS RORc MODULATORS
CN109152784B (zh) 2016-03-16 2021-12-28 库拉肿瘤学公司 经取代的menin-mll抑制剂及使用方法
AU2017246452C1 (en) 2016-04-06 2021-06-03 The Regents Of The University Of Michigan MDM2 protein degraders
US20190054097A1 (en) 2016-04-21 2019-02-21 Bioventures, Llc Compositions targeting senescent cells and the uses thereof
JP6936498B2 (ja) 2016-04-21 2021-09-15 バイオベンチャーズ・リミテッド・ライアビリティ・カンパニーＢｉｏＶｅｎｔｕｒｅｓ， ＬＬＣ 抗アポトーシス性Ｂｃｌ−２ファミリータンパク質の分解を誘導する化合物及びその使用
KR102605996B1 (ko) 2016-08-30 2023-11-27 다우 글로벌 테크놀로지스 엘엘씨 아크롤레인의 농도의 저감 방법
KR20190075084A (ko) 2016-10-10 2019-06-28 셀러랜트 세라퓨틱스 인코퍼레이티드 이소퀴놀리디노벤조디아제핀 (iqb)-1-(클로로메틸)-2,3-디히드로-1h-벤조[e]인돌 (cbi) 이량체
WO2018071606A1 (en) 2016-10-11 2018-04-19 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor
WO2018075820A2 (en) 2016-10-20 2018-04-26 Celgene Corporation Cereblon-based heterodimerizable chimeric antigen receptors
JP2020514252A (ja) 2016-12-08 2020-05-21 アイカーン スクール オブ メディスン アット マウント シナイ Ｃｄｋ４／６媒介性がんを治療するための組成物および方法
BR112019015484A2 (pt) 2017-01-31 2020-04-28 Arvinas Operations Inc ligantes de cereblon e compostos bifuncionais compreendendo os mesmos
TWI791552B (zh) * 2017-07-10 2023-02-11 美商西建公司 抗增生化合物及其使用方法
US10513515B2 (en) 2017-08-25 2019-12-24 Biotheryx, Inc. Ether compounds and uses thereof
CN109912655B (zh) 2017-12-13 2021-12-10 上海科技大学 Alk蛋白降解剂及其抗肿瘤应用
EA202092830A1 (ru) * 2018-05-23 2021-04-08 Селджин Корпорейшн Антипролиферативные соединения и биспецифические антитела к bcma и cd3 для комбинированного применения
CN108690020A (zh) 2018-07-04 2018-10-23 清华大学 一种靶向降解bet蛋白的化合物及其应用
CN108794453A (zh) 2018-07-05 2018-11-13 清华大学 一种靶向降解fak蛋白的化合物及其应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013519675A (ja) 2010-02-11 2013-05-30 セルジーン コーポレイション アリールメトキシイソインドリン誘導体、それを含む組成物、及びその使用方法
JP2015524478A (ja) 2012-08-09 2015-08-24 セルジーン コーポレイション ３−（４−（（４−（モルホリノメチル）ベンジル）オキシ）−１−オキソイソインドリン−２−イル）ピペリジン−２，６−ジオンを使用する癌の治療方法

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022516989A (ja) * 2019-01-09 2022-03-03 セルジーン コーポレイション （ｓ）－４－（４－（４－（（（２－（２，６－ジオキソピペリジン－３－イル）－１－オキソイソインドリン－４－イル）オキシ）メチル）ベンジル）ピペラジン－１－イル）－３－フルオロベンゾニトリルを含む医薬組成物及びその使用方法
JP2022518175A (ja) * 2019-01-09 2022-03-14 セルジーン コーポレイション （ｓ）－４－（４－（４－（（（２－（２，６－ジオキソピペリジン－３－イル）－１－オキソイソインドリン－４－イル）オキシ）メチル）ベンジル）ピペラジン－１－イル）－３－フルオロベンゾニトリルを含む固体形態及びその塩、ならびにそれらを含む組成物及びその使用方法
JP7483722B2 (ja) 2019-01-09 2024-05-15 セルジーン コーポレイション （ｓ）－４－（４－（４－（（（２－（２，６－ジオキソピペリジン－３－イル）－１－オキソイソインドリン－４－イル）オキシ）メチル）ベンジル）ピペラジン－１－イル）－３－フルオロベンゾニトリルを含む固体形態及びその塩、ならびにそれらを含む組成物及びその使用方法
JP7489989B2 (ja) 2019-01-09 2024-05-24 セルジーン コーポレイション （ｓ）－４－（４－（４－（（（２－（２，６－ジオキソピペリジン－３－イル）－１－オキソイソインドリン－４－イル）オキシ）メチル）ベンジル）ピペラジン－１－イル）－３－フルオロベンゾニトリルを含む医薬組成物及びその使用方法

Also Published As

Publication number Publication date
CA3069138A1 (en) 2019-01-17
RS66162B1 (sr) 2024-12-31
IL271889A (en) 2020-02-27
TW201907923A (zh) 2019-03-01
US20200253964A1 (en) 2020-08-13
AU2018301335A1 (en) 2020-01-30
MX2023000085A (es) 2023-02-09
US20190008852A1 (en) 2019-01-10
TWI791552B (zh) 2023-02-11
TW202319385A (zh) 2023-05-16
AU2018301335B2 (en) 2022-09-15
KR20200026980A (ko) 2020-03-11
IL271889B2 (en) 2023-03-01
US10357489B2 (en) 2019-07-23
EP3651766A1 (en) 2020-05-20
JP2020526534A (ja) 2020-08-31
US11185543B2 (en) 2021-11-30
SMT202400470T1 (it) 2025-01-14
HUE069137T2 (hu) 2025-02-28
SI3651766T1 (sl) 2025-02-28
CN110869021A (zh) 2020-03-06
US10675281B2 (en) 2020-06-09
ES2992913T3 (en) 2024-12-19
PT3651766T (pt) 2024-11-25
LT3651766T (lt) 2024-12-10
TWI830576B (zh) 2024-01-21
EP4467143A3 (en) 2025-01-29
US20190282567A1 (en) 2019-09-19
SG11202000143PA (en) 2020-02-27
US20240207255A1 (en) 2024-06-27
IL271889B (en) 2022-11-01
PL3651766T3 (pl) 2025-03-03
DK3651766T3 (da) 2024-11-18
AU2022287569A1 (en) 2023-02-02
ECSP20001149A (es) 2020-02-28
HRP20241553T1 (hr) 2025-01-17
EP4467143A2 (en) 2024-11-27
EP4467143B1 (en) 2026-03-11
BR112020000442A2 (pt) 2020-07-21
EP3651766B1 (en) 2024-09-11
CN110869021B (zh) 2023-06-30
WO2019014100A1 (en) 2019-01-17
US12029738B2 (en) 2024-07-09
NZ760649A (en) 2025-02-28
US20220280505A1 (en) 2022-09-08
CL2020000060A1 (es) 2020-07-31
ZA202000157B (en) 2021-08-25
KR102656934B1 (ko) 2024-04-16
AU2022287569B2 (en) 2025-02-20
SA520411007B1 (ar) 2024-08-18
CO2020000193A2 (es) 2020-04-24
FI3651766T3 (fi) 2024-11-18

Similar Documents

Publication Publication Date Title
JP7258009B2 (ja) 抗増殖化合物及びその使用方法
US12186311B2 (en) Antiproliferative compounds and second active agents for combined use
HK40120015A (en) 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-l-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-l-yl)-3-fluorobenzonitrile as antiproliferative compound
HK40029753A (en) 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-l-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-l-yl)-3-fluorobenzonitrile as antiproliferative compound
HK40029753B (en) 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-l-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-l-yl)-3-fluorobenzonitrile as antiproliferative compound
BR112020000442B1 (pt) Compostos antiproliferativos, composição farmacêutica compreendendo-os, uso dos referidos compostos e métodos para preparar compostos antiproliferativos
EA040549B1 (ru) Антипролиферативные соединения и способы их применения
EA045949B1 (ru) Антипролиферативные соединения и вторые активные агенты для комбинированного применения

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210708

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20210708

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210708

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220602

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220726

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20221024

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230307

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230404

R150 Certificate of patent or registration of utility model

Ref document number: 7258009

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250